[시장보고서]세계의 지혈제 및 조직 실링제 시장 : 제품별, 재료별, 용도별, 최종사용자별, 지역별 예측(-2032년)

세계의 지혈제 및 조직 실링제 시장 : 제품별, 재료별, 용도별, 최종사용자별, 지역별 예측(-2032년)

Global Hemostasis and Tissue Sealing Agents Market Research Report Information by Product, By Material, By Application, By End-User, and Region Forecast till 2032

상품코드 : 1563124 해당 상품은 즉시 배송 가능합니다

리서치사 : Market Research Future

발행일 : 2024년 08월

페이지 정보 : 영문 132 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 7,246,000

PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 5,950

￦ 8,710,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 7,250

￦ 10,614,000

PDF & Excel (Enterprise License)

PDF, Excel 보고서를 동일 기업이 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능하며, 인쇄 가능합니다.

한글목차

샘플 요청 목록에 추가

지혈제 및 조직 실링제 시장 규모는 2023년 83억 9,000만 달러, 2024년 90억 2,000만 달러에서 예측 기간 동안 8.04%의 복합 연간 성장률(CAGR)로 성장을 지속하여 2032년에는 181억 9,000만 달러 규모로 성장할 것으로 예상됩니다. 교통사고와 만성 혈액질환의 발생률 상승, 저침습 수술에 대한 세계의 수요, 고령화 등의 요인이 시장 확대의 원동력이 되고 있습니다.

만성 혈액 질환의 유병률 증가는 시장 성장을 가속하는 요인입니다. 혈우병이나 폰 Willebrand 병과 같은 특정 혈액 질환 환자는 응고 인자가 감소하기 때문에 출혈하기 쉽습니다. 혈액 응고를 촉진하고 출혈을 억제하는 지혈제는 이러한 질병을 가진 사람들에 대한 외과적 치료 및 약물 개입에 필요할 수 있습니다. International Society on Thrombosis and Hemostasis의 2022년 최신판에서는 정맥 혈전 색전증은 세계에서 매년 약 1,000만건 발생하고 있다고 추계되고 있습니다. 또한 이 조직에 따르면 유럽에서는 매년 54만 4,000명이 심부정맥혈전증(DVT)으로 사망하고 있습니다.

지역별 인사이트력

북미 시장은 2023년에 가장 큰 시장 점유율을 차지했습니다. 고령화, 만성질환 증가, 의료기술의 진보가 진행되고 있기 때문입니다. 환자 결과의 개선과 수술 후 합병증의 감소에 초점을 맞춘 이 시장은 R&D의 거점으로 발전하여 뛰어난 효능을 가진 신규 치료가 도입되게 되었습니다.

유럽 시장은 양호한 의료 정책과 상담을 포함한 병용 요법으로 2위 시장 점유율을 차지할 것으로 추정됩니다.

아시아태평양 시장은 2024년부터 2032년까지 가장 빠른 속도로 발전할 것으로 추정됩니다. 이는 급속한 경제 확대, 중간층 증가, 도시화의 발전으로 인한 것입니다. 이 지역의 인구 증가는 의료, 기술 및 소비자 제품에 대한 수요를 촉진하고 있습니다. 인프라, 교육, 기술에 대한 왕성한 투자는 산업의 발전과 혁신을 촉진하고 있습니다.

본 보고서에서는 세계의 지혈제 및 조직 실링제 시장을 조사했으며,, 시장 정의와 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모 추이와 예측, 각종 구분, 지역별 분석, 경쟁 환경, 주요 기업 프로파일 등을 정리했습니다.

영문목차

Global Hemostasis and Tissue Sealing Agents Market Research Report Information by Product (Topical Hemostat, Adhesive & Tissue Sealant), By Material (Chitosan-based Products, Mineral based Products), By Application (Trauma, General Surgery, Minimally Invasive Surgery, Gynecology Others), By End-User (Hospitals, Ambulatory Surgical Centers, Research Institutes), and Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032

Market Overview

In 2023, the market for hemostasis and tissue sealing agents was estimated to be worth USD 8.39 billion. The Hemostasis and Tissue Sealing Agents Market is expected to increase from USD 9.02 billion in 2024 to USD 18.19 billion by 2032, with a compound annual growth rate (CAGR) of 8.04% over the forecast period (2024-2032). Rising rates of traffic accidents and chronic blood problems, a global demand for minimally invasive procedures, and an aging population are driving market expansion.

The increasing prevalence of chronic blood diseases is another element driving market growth. Individuals with certain blood disorders, such as hemophilia or von Willebrand disease, are more likely to bleed because their clotting factors are compromised. Hemostasis drugs, which enhance blood clotting and limit bleeding, may be required in surgical procedures or medicinal interventions for people with these conditions. For example, the International Society on Thrombosis and Hemostasis' 2022 update estimates that approximately 10 million cases of venous thromboembolism occur globally each year. According to the same source, 544,000 persons in Europe die each year from Deep Vein Thrombosis (DVT).

Market Segment insights

Hemostasis and Tissue Sealing Agents Product-based market segmentation includes Topical Hemostat and adhesive & tissue sealant.

The market is segmented by material, which comprises chitosan-based products and mineral-based products.

The market is segmented by end user, which includes hospitals, ambulatory surgical centers, and research institutes.

Regional insights

The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American Hemostasis and Tissue Sealing Agents market had the biggest market share in 2023. Because of the aging population, the rising prevalence of chronic diseases, and the ongoing advancement of medical technology. With a focus on improving patient outcomes and lowering postoperative complications, the market has evolved into a hub for research and development, resulting in the introduction of novel treatments with superior efficacy.

The European Hemostasis and Tissue Sealing Agents market is estimated to account for the second-largest market share due to favorable health policies and a tendency toward combining Hemostasis and Tissue Sealing Agents, including counseling. Furthermore, the German Hemostasis and Tissue Sealing Agents market was found to have the greatest market share, while the French Hemostasis and Tissue Sealing Agents market is predicted to be the fastest-growing market in the European area.

The Asia-Pacific Hemostasis and Tissue Sealing Agents market is estimated to develop at the quickest rate between 2024 and 2032. This is the result of rapid economic expansion, a growing middle class, and greater urbanization. The region's growing population fuels demand for healthcare, technology, and consumer products. Robust investments in infrastructure, education, and technology drive industrial development and innovation.

The Middle East, Africa, and Latin America are all part of the Rest of the World. The primary drivers driving the rise of Hemostasis and Tissue Sealing Agents in the Middle East and Africa. MEA region has experienced. Increased healthcare spending and infrastructure expansion are boosting demand for innovative medical equipment.

Key Market Players

Johnson & Johnson (US), B Braun Medical Inc (Germany), Teleflex Incorporated (US), Medtronic (Ireland), Baxter (US), Medtrade Products Limited (UK), Axio Biosolutions Pvt Ltd (India), MIL Laboratories Pvt. Ltd (India), Becton, Dickinson, and Company (US), and Pfizer Inc (US) are the market's leading players.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
- 3.5.1 Primary Research Data Flow:
- 3.5.2 Primary Research: Number of Interviews conducted
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
- 3.7.1 Data forecasting Technique
3.8 DATA MODELLING
- 3.8.1 Microeconomic Factor Analysis:
- 3.8.2 Data Modelling:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.1 DRIVERS
- 4.1.1 Growing Incidences Of Road Accidents And Chronic Blood Disorders
- 4.1.2 Growing Preference Of Minimally Invasive Procedures
4.2 RESTRAINTS
- 4.2.1 High Costs and Stringent Regulatory Requirements
4.3 OPPORTUNITY
- 4.3.1 Growing Incidences Of Road Accidents And Growing Geriatric Population

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 Research & Development
- 5.1.2 Manufacturing
- 5.1.3 Distribution
- 5.1.4 Marketing & Sales
- 5.1.5 Post-Sales Monitoring
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 bargaining power of buyers
- 5.2.2 Bargaining Power of Suppliers
- 5.2.3 Threat of New Entrants
- 5.2.4 THREAT OF SUBSTITUTES
- 5.2.5 Intensity of Rivalry
5.3 IMPACT OF COVID-19
5.4 HEMOSTASIS AND TISSUE SEALING AGENTS FOR MILITARY PURPOSE

6 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY PRODUCT

6.1 OVERVIEW
6.2 TOPICAL HEMOSTAT
- 6.2.1 Active
- 6.2.2 Mechanical
- 6.2.3 Flowable
6.3 ADHESIVE & TISSUE SEALANT
- 6.3.1 Synthetic Tissue Sealant
- 6.3.2 Natural Tissue Sealant
- 6.3.3 Adhesion Barrier Products

7 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY MATERIAL

7.1 OVERVIEW
7.2 CHITOSAN-BASED PRODUCTS
7.3 MINERAL BASED PRODUCTS

8 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY APPLICATION

8.1 OVERVIEW
8.2 TRAUMA
- 8.2.1 Burns
- 8.2.2 Accidents
  - 8.2.2.1 Major Accidents
  - 8.2.2.2 Minor Accidents
- 8.2.3 Others
8.3 GENERAL SURGERY
8.4 MINIMALLY INVASIVE SURGERY
8.5 GYNAECOLOGY
8.6 OTHERS

9 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY END USER

9.1 OVERVIEW
9.2 HOSPITALS
- 9.2.1 Public
- 9.2.2 Private
- 9.2.3 Military
9.3 AMBULATORY SURGICAL CENTERS
- 9.3.1 Independent Ambulatory Surgical Centers
- 9.3.2 Military Ambulatory Surgical Centers
9.4 RESEARCH INSTITUTES

10 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
10.3 EUROPE
- 10.3.1 Germany
- 10.3.2 France
- 10.3.3 UK
- 10.3.4 Italy
- 10.3.5 spain
- 10.3.6 Rest of Europe
10.4 ASIA-PACIFIC
- 10.4.1 China
- 10.4.2 India
- 10.4.3 Japan
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia-Pacific
10.5 REST OF THE WORLD
- 10.5.1 Middle East & Africa
- 10.5.2 South America

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS,
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 product launch / Product approval
- 11.6.2 Acquisition

12 COMPANY PROFILES

12.1 JOHNSON & JOHNSON SERVICES, INC
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 productS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 B. BRAUN SE
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 products OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 KEY STRATEGIES
12.3 MIL LABORATORIES PVT. LTD
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 productS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 KEY STRATEGIES
12.4 BECTON, DICKINSON, AND COMPANY
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 KEY STRATEGIES
12.5 PFIZER INC.
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 SWOT ANALYSIS
- 12.5.6 KEY STRATEGIES
12.6 TELEFLEX INCORPORATED
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 TELEFLEX INCORPORATED: kEY DEVELOPMENTS
- 12.6.6 KEY STRATEGIES
12.7 MEDTRONIC
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
12.8 BAXTER
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
12.9 MEDTRADE PRODUCTS LIMITED
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 SWOT ANALYSIS
- 12.9.6 KEY STRATEGIES
12.10 AXIO BIOSOLUTIONS PVT LTD
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES

한글목차

목차

제1장 주요 요약

제2장 시장 개요

제3장 조사 방법

제4장 시장 역학

제5장 시장 요인 분석

제6장 세계의 지혈제 및 조직 실링제 시장 : 제품별

제7장 세계의 지혈제 및 조직 실링제 시장 : 재료별

제8장 세계의 지혈제 및 조직 실링제 시장 : 용도별

제9장 세계의 지혈제 및 조직 실링제 시장 : 최종 사용자별

제10장 세계의 지혈제 및 조직 실링제 시장 :지역별

제11장 경쟁 구도

제12장 기업 프로파일

제13장 데이터 인용